If surface markers specific to cancer-promoting CAFs are identified and monoclonal antibodies are established, NIR-PIT targeting the cancer-promoting CAFs would induce more significant therapeutic effects than the present NIR-P’IT with αFAP-IR700 in PDAC. Here, AFAP1 is linked to cancer.